Latest News and Press Releases

Helsinn announces European approval of the IV formulation of AKYNZEO® (fosnetupitant / palonosetron) Lugano, Switzerland, March 23, 2020 – Helsinn, the Swiss pharmaceutical group focused on building...

Helidon Xhixha and Giacomo “Jack” Bragliapresent the artwork The Twin Bottles: Message in a BottleAn environmental message Principality of Monaco, Yacht Club de Monaco Marina The Twin Bottles:...

New Insights on Mechlorethamine/Chlormethine gel presented at 4th World Congress of Cutaneous Lymphomas Lugano, Switzerland, February 14, 2020 – Helsinn, the Swiss pharmaceutical group focused on...

Lyfebulb and Helsinn Announce the Winners of the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award   MONACO, PRINCIPALITY OF MONACO, AND NEW YORK, NY, USA, January 31, 2020:...

Helsinn Group Grants Exclusive Licensing Rights to Berlin-Chemie AG, a company of the Menarini Group, for ONICIT®/ALOXI® and AKYNZEO® in Russia and CIS region Berlin-Chemie AG has been granted...

Lyfebulb and Helsinn Announce 11 Finalists for the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award       The Award recognizes Patient Entrepreneurs demonstrating outstanding...

Helsinn appoints Eric Cornut and Lonnie Moulder to the Board of Directors   Lugano, Switzerland, January 13, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care...

Lugano, Switzerland, December 13, 2019 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, is presenting a scientific poster assessing acute care involving...

Helsinn supported ‘70 Years of Cancer Care in China’ celebratory event in Shanghai Lugano, Switzerland, November 14, 2019 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer...

Helsinn attends 4th Annual Sino-Swiss Business Awards Lugano, Switzerland, November 7, 2019 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, attended the 4th...